EGFR and non-small cell lung carcinoma: In the study of Azuma et al. 53, inhibition of EGFR signaling by erlotinib down-regulated surface expression of PD-L1 in EGFR mutation-positive NSCLC cells, but not in the EGFR wild-type cells.